Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth ...

Cambridge headquartered global pharmaceutical company AstraZeneca took its spending on China plays in the last month to ...

Friday’s deal with CSPC fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

AstraZeneca will pay CSPC upfront fee of $110 million Additional potential payments of up to $5.22 billion to CSPC Deal latest of AstraZeneca efforts to bolster China business, AI The deal marks ...